Literature DB >> 22118668

BCR-ABL1 kinase: hunting an elusive target with new weapons.

Tomasz Skorski1.   

Abstract

Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2011        PMID： 22118668      PMCID： PMC3228864          DOI： 10.1016/j.chembiol.2011.11.001

Source DB:  PubMed          Journal:  Chem Biol        ISSN： 1074-5521


  10 in total

Review 1.  Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.

Authors:  Stephen B Marley; Myrtle Y Gordon
Journal:  Clin Sci (Lond)       Date:  2005-07       Impact factor: 6.124

2.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

3.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Authors:  T Skorski; M Nieborowska-Skorska; N C Nicolaides; C Szczylik; P Iversen; R V Iozzo; G Zon; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors:  Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

5.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

6.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

7.  Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Authors:  Florian Grebien; Oliver Hantschel; John Wojcik; Ines Kaupe; Boris Kovacic; Arkadiusz M Wyrzucki; Gerald D Gish; Sabine Cerny-Reiterer; Akiko Koide; Hartmut Beug; Tony Pawson; Peter Valent; Shohei Koide; Giulio Superti-Furga
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 8.  New drugs for chronic myelogenous leukemia.

Authors:  Fabio P S Santos; Alfonso Quintás-Cardama
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

9.  Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Authors:  Jianming Zhang; Francisco J Adrián; Wolfgang Jahnke; Sandra W Cowan-Jacob; Allen G Li; Roxana E Iacob; Taebo Sim; John Powers; Christine Dierks; Fangxian Sun; Gui-Rong Guo; Qiang Ding; Barun Okram; Yongmun Choi; Amy Wojciechowski; Xianming Deng; Guoxun Liu; Gabriele Fendrich; André Strauss; Navratna Vajpai; Stephan Grzesiek; Tove Tuntland; Yi Liu; Badry Bursulaya; Mohammad Azam; Paul W Manley; John R Engen; George Q Daley; Markus Warmuth; Nathanael S Gray
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962

10.  The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Authors:  Christopher A Eide; Lauren T Adrian; Jeffrey W Tyner; Mary Mac Partlin; David J Anderson; Scott C Wise; Bryan D Smith; Peter A Petillo; Daniel L Flynn; Michael W N Deininger; Thomas O'Hare; Brian J Druker
Journal:  Cancer Res       Date:  2011-04-19       Impact factor: 12.701
  10 in total
  15 in total

Review 1.  Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 2.  Therapeutic strategies for tauopathies and drug repurposing as a potential approach.

Authors:  Majedul Islam; Fengyun Shen; Deepika Regmi; Deguo Du
Journal:  Biochem Pharmacol       Date:  2022-02-24       Impact factor: 6.100

3.  BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Authors:  A Slupianek; R Falinski; P Znojek; T Stoklosa; S Flis; V Doneddu; D Pytel; E Synowiec; J Blasiak; A Bellacosa; T Skorski
Journal:  Leukemia       Date:  2012-10-09       Impact factor: 11.528

4.  Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

Authors:  M Nieborowska-Skorska; G Hoser; A Hochhaus; T Stoklosa; T Skorski
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

Review 5.  Is human immunodeficiency virus-mediated dementia an autophagic defect that leads to neurodegeneration?

Authors:  Eleonora Passeri; Italo Mocchetti; Charbel Moussa
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

6.  Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.

Authors:  Irina Lonskaya; Michaeline L Hebron; Nicole M Desforges; Joel B Schachter; Charbel E-H Moussa
Journal:  J Mol Med (Berl)       Date:  2013-12-13       Impact factor: 4.599

7.  BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models.

Authors:  Hisae Nishioka; Norie Tooi; Takehisa Isobe; Norio Nakatsuji; Kazuhiro Aiba
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

8.  Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance.

Authors:  Irina Lonskaya; Michaeline L Hebron; Nicole M Desforges; Alexander Franjie; Charbel E-H Moussa
Journal:  EMBO Mol Med       Date:  2013-07-04       Impact factor: 12.137

9.  Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.

Authors:  Fernando Pagan; Michaeline Hebron; Ellen H Valadez; Yasar Torres-Yaghi; Xu Huang; Reversa R Mills; Barbara M Wilmarth; Hellen Howard; Connell Dunn; Alexis Carlson; Abigail Lawler; Sean L Rogers; Ramsey A Falconer; Jaeil Ahn; Zhaoxia Li; Charbel Moussa
Journal:  J Parkinsons Dis       Date:  2016-07-11       Impact factor: 5.568

10.  Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

Authors:  Michaeline L Hebron; Irina Lonskaya; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2013-05-10       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.